Spots Global Cancer Trial Database for Personalized Targeted Therapy in Refractory or Relapsed Cancer in Childhood
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Personalized Targeted Therapy in Refractory or Relapsed Cancer in Childhood
Official Title: Personalized Targeted Therapy in Refractory or Relapsed Cancer in Childhood(TRICEPS Study)
Study ID: NCT02242552
Conditions
Interventions
Study Description
Brief Summary: A new research paradigm that involves sequencing tumor DNA/RNA to identify driver mutations, select among the Health Canada approved drugs (for adult cancers) known to block certain oncogenic pathways, and recommend these drugs to the treating physician, without taking into account the tumor histology. In this paradigm, the treatment is targeted to the actionable mutation(s) i.e. those driving oncogenesis. It is also personalized to the molecular signature of the patient's tumor, irrespective of its histopathological subtype. The experience of the investigators team in genomics, including next generation sequencing and bioinformatic analysis combined with the clinical expertise, bring at last this approach within our technical capacities. In parallel, the number of Health Canada-approved drugs (which have been tested in a pediatric setting) designed to interfere with oncogenesis pathways is increasing exponentially.
Detailed Description:
Keywords
Eligibility
Minimum Age: 1 Month
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
CHU Sainte-Justine, Montréal, Quebec, Canada
Contact Details
Name: Monia Marzouki, MD
Affiliation: St. Justine's Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
